AI Tools for Healthcare: What Actually Holds Up Under Scrutiny
Healthcare AI attracts enormous claims and deserves more scrutiny than most sectors. The stakes are different when wrong outputs could affect clinical decisions. This article focuses on what has been validated in actual clinical use, where real adoption has happened, and where the technology remains genuinely experimental.
What has demonstrated real value
Clinical documentation and ambient scribing
This is the category where healthcare AI has the clearest demonstrated value and the highest adoption rate. Tools that listen to a patient-physician conversation and generate structured clinical notes — SOAP notes, discharge summaries, visit documentation — are saving physicians 1-2 hours of administrative work per day in documented deployments.
Nuance DAX Copilot (part of Microsoft) is the category leader, used by hundreds of health systems in the US and internationally. DAX listens to patient-physician conversations, structures the output as a clinical note, and the physician reviews and approves before it enters the EHR. The time savings are consistent across specialties: 2-3 minutes of documentation work replaces 20-30 minutes.
Nabla and Suki AI operate in the same category with similar workflows. Nabla has particular traction in Europe and has published peer-reviewed outcomes data on documentation quality. Suki integrates with major EHR systems and has FDA 510(k) clearance for its dictation features.
The value proposition is well-established. Physician burnout from administrative burden is a documented problem. Tools that reduce that burden without compromising documentation quality have strong evidence and clinical acceptance.
Medical imaging analysis
AI in radiology and pathology has a longer research history than ambient scribing and has produced several FDA-cleared tools.
Aidoc provides AI-powered triage for radiology — flagging urgent findings (intracranial hemorrhage, pulmonary embolism, aortic dissection) so radiologists review the highest-priority cases first. Multiple health systems have published outcomes data showing reduction in time-to-treatment for flagged conditions.
Viz.ai has FDA clearance for stroke triage and operates similarly: AI detection of large vessel occlusion triggers faster notification to the stroke team. Time-to-treatment for stroke is one of the clearest clinical outcome metrics, and published data shows meaningful improvements in systems using Viz.ai.
These tools are not replacing radiologists. They are decision-support tools that improve workflow and reduce the risk of time-critical findings going unreviewed at the bottom of a large worklist.
Drug discovery and research acceleration
Tools like Insilico Medicine and Recursion apply AI to identifying drug candidates and predicting molecular properties. Insilico generated a novel drug candidate (INS018_055 for IPF) that reached Phase II clinical trials in 2024 — a milestone that matters because it validates the generative chemistry workflow.
This category operates on much longer timescales than clinical tools. The value is in accelerating early-stage research, not producing ready-to-prescribe treatments. Legitimate caution: the early results are promising but clinical success rates for AI-designed drugs are not yet separable from statistical variation given small sample sizes.
Where significant limitations remain
Clinical decision support
AI tools that assist with diagnosis, treatment selection, or prescribing face a high evidence bar and are right to face it. Most commercially available "clinical decision support AI" tools are not well-validated on diverse patient populations. Publication bias in healthcare AI research is a documented problem — studies that show the tool works are published more often than studies that show it does not.
The specific failure mode that matters most: AI systems trained on historical data from one patient population often perform significantly worse on different populations. A system trained on data from a well-resourced urban academic medical center may not perform well on rural patients, elderly patients, or patients with multiple comorbidities that were underrepresented in training data.
Before implementing any AI clinical decision support tool, the questions to ask are: what population was this trained on, has it been validated on your patient population, and is there outcome data from deployments in comparable settings.
General AI tools (ChatGPT, Claude) in clinical contexts
General-purpose AI tools are not appropriate as clinical reference tools. They produce plausible-sounding medical information but are not validated against clinical evidence standards, are not regularly updated as guidelines change, and can produce confident-sounding incorrect answers on rare conditions or recent guideline changes.
They are useful for non-clinical tasks: documentation drafting, administrative communication, patient-facing education material drafts that are reviewed by a clinician before distribution. They are not appropriate for clinical reasoning or treatment decision support without significant human oversight.
Privacy and compliance
Most commercial AI tools process data through cloud servers. Using patient-identified data with commercial AI tools raises HIPAA compliance questions that require legal and compliance review. BAAs (Business Associate Agreements) cover contractual liability, but they do not solve the underlying security risk of patient data on external servers.
Healthcare organizations using AI tools with patient data should require BAAs and should understand exactly what data is retained, for how long, and whether it is used for model training.
The tools worth evaluating
Nuance DAX Copilot — ambient scribing with the strongest health system adoption and Microsoft/Epic integration. Enterprise pricing through Microsoft.
Nabla — ambient scribing with strong European deployments, published clinical data, and competitive pricing relative to DAX. Pricing from $29/physician/month.
Aidoc — radiology AI for urgent finding detection, FDA-cleared for multiple conditions. Enterprise pricing.
Viz.ai — stroke and cardiovascular triage AI, FDA clearance, peer-reviewed outcomes. Enterprise pricing.
The honest position
Healthcare AI is a domain where "wait and see" is often the appropriate response to new tools. The tools with demonstrated value — ambient scribing, radiology triage, imaging analysis — have years of deployment data and published outcomes. The tools making broader claims about clinical decision support or diagnosis often lack the validation evidence that the risk profile requires.
The right question is not "does this use AI?" but "does this have evidence of improved outcomes in populations similar to mine?" If the answer requires reading between the lines of marketing material, that is informative.